Cost‐effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers

Current clinical guidelines recommend earlier, more intensive breast cancer screening with both magnetic resonance imaging (MRI) and mammography for women with breast cancer susceptibility gene (BRCA) mutations. Unspecified details of screening schedules are a challenge for implementing guidelines.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  Joseph A Hill.  United States Life Tables , 2013 .

[3]  Elisabeth Cardis,et al.  Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) , 2012, BMJ : British Medical Journal.

[4]  Sheila Weinmann,et al.  Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. , 2012, JAMA.

[5]  Linda Humphrey,et al.  Appropriate Use of Screening and Diagnostic Tests to Foster High-Value, Cost-Conscious Care , 2012, Annals of Internal Medicine.

[6]  L. Snyder.  American College of Physicians Ethics Manual , 2012, Annals of Internal Medicine.

[7]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[8]  G. Hortobagyi,et al.  Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer , 2011, Cancer.

[9]  Stephen R Grobmyer,et al.  Utilization of minimally invasive breast biopsy for the evaluation of suspicious breast lesions. , 2011, American journal of surgery.

[10]  Douglas K Owens,et al.  High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions , 2011, Annals of Internal Medicine.

[11]  A. Neugut,et al.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers , 2011, Breast Cancer Research and Treatment.

[12]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Feig,et al.  Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening. , 2010, Radiologic clinics of North America.

[14]  E. Arias,et al.  United States life tables, 2006. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[15]  A. Abernethy,et al.  Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. , 2010, JAMA.

[16]  G. Gazelle,et al.  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. , 2010, Radiology.

[17]  Constantine Gatsonis,et al.  Comparison of acquisition parameters and breast dose in digital mammography and screen-film mammography in the American College of Radiology Imaging Network digital mammographic imaging screening trial. , 2010, AJR. American journal of roentgenology.

[18]  G Scott Gazelle,et al.  Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[20]  D. Plewes,et al.  Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer , 2008, Annals of Internal Medicine.

[21]  D. Coyle,et al.  Wage losses in the year after breast cancer: extent and determinants among Canadian women. , 2008, Journal of the National Cancer Institute.

[22]  M. Weinstein,et al.  Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. , 2008, Radiology.

[23]  Jean B. Cormack,et al.  Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. , 2008, Radiology.

[24]  M. Leavitt,et al.  Department of Health and Human Services , 2007, Disaster Medicine and Public Health Preparedness.

[25]  Laura Cortesi,et al.  Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. , 2007, Radiology.

[26]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[27]  A. Kurian,et al.  A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Karla Kerlikowske,et al.  Performance benchmarks for screening mammography. , 2006, Radiology.

[29]  J Shannon Swan,et al.  Process Utility in Breast Biopsy , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  J. Benítez,et al.  Histopathology of BRCA1- and BRCA2-associated breast cancer. , 2006, Critical reviews in oncology/hematology.

[31]  Bruce L Daniel,et al.  Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. , 2006, JAMA.

[32]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Linden,et al.  The cost of adjuvant chemotherapy in patients with early‐stage breast carcinoma , 2005, Cancer.

[34]  C. D'Orsi,et al.  Diagnostic Performance of Digital Versus Film Mammography for Breast-Cancer Screening , 2005, The New England journal of medicine.

[35]  Jessica W T Leung,et al.  Performance benchmarks for diagnostic mammography. , 2005, Radiology.

[36]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[37]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[38]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[39]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[40]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[41]  Erik Holmberg,et al.  Radiation Effects on Breast Cancer Risk: A Pooled Analysis of Eight Cohorts , 2002, Radiation research.

[42]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[43]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Emanuel,et al.  Influence of age on Medicare expenditures and medical care in the last year of life. , 2001, JAMA.

[45]  K. Langa,et al.  Estimating the cost of informal caregiving for elderly patients with cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A S Detsky,et al.  Screening for breast cancer: time, travel, and out-of-pocket expenses. , 1999, Journal of the National Cancer Institute.

[47]  Staff,et al.  American College of Physicians Ethics Manual , 1992, Annals of Internal Medicine.

[48]  A. Elster.  Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006 , 2011 .

[49]  C. D'Orsi,et al.  Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. , 2010, Journal of the American College of Radiology : JACR.

[50]  I. Leitman,et al.  Quality assurance initiative at one institution for minimally invasive breast biopsy as the initial diagnostic technique. , 2009, Journal of the American College of Surgeons.

[51]  W. Lawrence,et al.  Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. , 2005, Journal of general internal medicine.

[52]  Injury rates by industry 1970, BLS Report 406, Department of Labor, Bureau of Labor Statistics. , 1972, IMS, Industrial medicine and surgery.

[53]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.